Q2 2024 Voyager Therapeutics Inc Earnings Call Transcript
Key Points
- Voyager Therapeutics Inc (VYGR) dosed the first healthy volunteers in the Phase 1a single ascending dose trial of VY7523, their anti-tau antibody for Alzheimer's disease.
- The company completed a pre-IND meeting with the FDA and initiated GLP toxicology studies for VY9323, their SOD1 silencing gene therapy program for ALS.
- Voyager Therapeutics Inc (VYGR) selected a development candidate in their GBA1 gene therapy program partnered with Neurocrine, triggering a $3 million milestone payment.
- The company presented significant data at ASGCT 2024, showcasing their second-generation TRACER capsids and their potential in CNS gene therapy.
- Voyager Therapeutics Inc (VYGR) ended the second quarter with a strong cash position of approximately $371 million, providing runway through multiple clinical data readouts into 2027.
- The company’s tau silencing gene therapy program is still in preclinical stages, with an IND filing not expected until 2026, indicating a longer timeline to potential market entry.
- There are uncertainties regarding the efficacy and safety of their anti-tau antibody, VY7523, as previous N-terminal directed antibodies have been unsuccessful in clinical trials.
- The competitive landscape for anti-tau therapies is crowded, with multiple companies pursuing similar approaches, potentially impacting market share and differentiation.
- The success of their gene therapy programs is contingent on overcoming significant delivery challenges posed by the blood-brain barrier, which remains a high-risk factor.
- Voyager Therapeutics Inc (VYGR) relies heavily on partnerships for several of their programs, which may limit their control over development timelines and strategic decisions.
Good afternoon, and welcome to the Voyager Therapeutics second-quarter 2024 financial results conference call. (Operator Instructions) Please note that today's call is being recorded. Replay of today's call will be available on the Investors section of the company website approximately two hours after completion of this call.
I would now like to turn the call over to Trista Morrison, Chief Corporate Affairs Officer at Voyager.
Thank you, and good afternoon. We issued our second-quarter 2024 financial results press release this afternoon. The press release and 10-Q are available on our website.
Joining me on today's call are Dr. Al Sandrock, our Chief Executive Officer; Dr. Toby Ferguson, our Chief Medical Officer; and Dr. Nathan Jorgensen, our Chief Financial Officer. We will also be joined for the Q&A portion of the call by Dr. Todd Carter, our Chief Scientific Officer.
Before we get started, I'd like to remind everyone
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
